# Stoke Therapeutics, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Stoke Therapeutics, Inc.). ## Overview Stoke Therapeutics, Inc. is a U.S.-based biopharmaceutical company focused on developing RNA-targeted medicines for severe genetic diseases. Its pipeline includes zorevunersen (STK-001) for Dravet syndrome, STK-002 for autosomal dominant optic atrophy, and additional product candidates developed through its TANGO platform and collaboration structure. ## Products & services • zorevunersen (STK-001) for Dravet syndrome • STK-002 for autosomal dominant optic atrophy • TANGO-based RNA modulation drug discovery • Collaboration and licensing arrangements with partners • Clinical development of rare-disease therapeutics - **Lead clinical programs** (70%) — Drug candidates in human clinical development, including zorevunersen and STK-002. - **Collaboration and licensing revenue** (30%) — Revenue earned from licensing IP and performing partnered development activities. - zorevunersen (STK-001) for Dravet syndrome - STK-002 for autosomal dominant optic atrophy - TANGO-based RNA modulation drug discovery - Collaboration and licensing arrangements with partners - Clinical development of rare-disease therapeutics ## Customers Stoke’s direct commercial customers are not yet established because its products are still in development; instead, revenue currently comes from collaboration partners such as Biogen and Acadia. If approved, its medicines would be prescribed by healthcare providers and reimbursed by third-party payors, with access shaped by specialty neurology and rare-disease treatment pathways. - **Strategic collaboration partners** (primary) — Biogen and Acadia fund, develop, and potentially commercialize selected programs under alliance terms. - **Neurologists and specialty prescribers** (primary) — Physicians treating Dravet syndrome or other rare genetic disorders who would prescribe approved products. - **Third-party payors** (secondary) — Commercial and government payors that would influence access, reimbursement, and uptake. - **Rare-disease patients** (primary) — Patients with severe genetic disorders who are the intended beneficiaries of the therapies. - Biogen as an ex-North America collaboration partner - Acadia Pharmaceuticals as a development/commercial partner - Healthcare providers who would prescribe approved therapies - Third-party payors that would determine reimbursement access - Rare-disease patients and caregivers as end users ## Geography Stoke is headquartered in the United States and conducts its core research and development activities from there. Its commercial footprint is expected to be split between North America and ex-North America through partnerships, with Biogen covering development and commercialization outside North America for zorevunersen. - United States is the company’s operating and development base - North America is the intended direct commercialization region - Biogen covers zorevunersen outside North America - Future alliances may extend reach into other large markets - Revenue is collaboration-based rather than geography-based today ## Strategy Stoke’s strategy centers on advancing its RNA-targeted rare-disease pipeline through clinical development and regulatory milestones. It also uses alliances to share development and commercialization responsibilities, especially outside North America, while preserving flexibility to build its own sales capability if products are approved. - **Advance zorevunersen toward approval** (short-term) — It is the company’s most advanced and strategically important program. - **Develop and de-risk STK-002 and other pipeline assets** (medium-term) — Broader pipeline success reduces dependence on a single lead program. - **Leverage partnerships for commercialization** (medium-term) — Alliances extend geographic reach and reduce the need for a large internal sales force. - Advance zorevunersen through late-stage clinical development - Progress STK-002 and other pipeline programs - Use alliances to expand reach beyond internal resources - Retain optionality to build a U.S. commercial organization - Fund development through collaborations and capital markets ## Risks Stoke is an early-stage biotechnology company, so its value depends heavily on successful clinical development, regulatory approval, and eventual commercialization of a small number of programs. It also faces financing, partnership execution, intellectual property, and healthcare reimbursement risks that are typical for rare-disease drug developers but especially important given its limited operating history. - **Clinical development failure** [critical] — Lead programs may not show sufficient safety or efficacy in later-stage trials. - **Regulatory approval risk** [high] — FDA or foreign regulators may delay, restrict, or deny approval. - **Partner commercialization risk** [high] — Biogen, Acadia, or future partners may not devote enough resources to launch and marketing. - **Financing and dilution risk** [high] — The company expects to need additional capital to fund development and operations. - **Intellectual property risk** [medium] — Protection of RNA platform and product rights is essential to commercialization value. - **Healthcare compliance risk** [medium] — Future sales and distribution arrangements must comply with anti-kickback and fraud laws. - Clinical failure or delay could materially impair the pipeline - Regulatory approval is uncertain and may be narrower than expected - Rare-disease patient identification can slow trial enrollment - Partner execution risk could limit commercialization and revenue - Additional financing may be needed before products generate sales ## Accounting The most important accounting issue is collaboration revenue recognition, because revenue is driven by satisfying performance obligations under the Acadia and Biogen agreements rather than product sales. Investors should also watch judgment-heavy estimates tied to clinical development, stock-based compensation, and any future capitalization or impairment decisions as the pipeline advances. - **Collaboration and license revenue recognition** — Can create large quarter-to-quarter swings in reported revenue - **Clinical development cost estimation** — Affects operating expense timing and comparability - **Stock-based compensation** — Influences reported operating loss and dilution analysis - **Impairment and valuation judgments** — Could affect future earnings if asset values change - Collaboration revenue is recognized as performance obligations are satisfied - IP license revenue can create large timing swings between quarters - R&D expense reflects clinical trial and development program activity - Stock-based compensation is a meaningful non-cash expense - Estimates and assumptions affect asset, liability, and contingent item values --- *Last updated: 2026-04-29T05:00:23.467742+00:00*